Introduction
Modern medicine is undergoing a transformation toward geroscience, the study of the biological mechanisms of aging. The goal is no longer merely to treat diseases, but to extend healthspan—the period of life spent in full health and functionality.
In the book Bad Influence, the author analyzes the risks associated with this shift. Readers will discover how the commercial longevity movement is outpacing science and why the digitalization of healthcare may deepen social inequalities.
Geroscience and the Pursuit of Extended Healthspan
Traditional prevention focuses on the early detection of specific pathologies. Geroscience differs by targeting the aging process itself as the common denominator for many diseases. Rather than treating diabetes or cancer in isolation, it seeks to modify the mechanisms that increase susceptibility to all these conditions simultaneously.
However, the author warns of a gap between theory and practice. A prime example is the longevity movement, which commercializes biological hypotheses (e.g., NAD+ and NMN supplements) before they have been clinically verified in humans. Consequently, the market sells the promise of rejuvenation while science is still investigating basic mechanisms.
Geroscience and the Conflict Between Public Prevention and Luxury Biohacking
While traditional geriatrics cares for ailing seniors, geroscience aims to delay the onset of multimorbidity. This creates a conflict between affordable public prophylaxis and luxury biohacking. The author highlights the phenomenon of the wellth divide, where economic capital is converted into biological capital.
Personalized optimization (such as Bryan Johnson's Blueprint program) is becoming a project for the ultra-wealthy. This could lead to a scenario where the affluent purchase extended physical functionality, while the public health system struggles with basic staffing and material shortages.
The Evidence Gap Between Mechanism and Clinical Effect
Many anti-aging substances, such as rapamycin or metformin, show efficacy in animals, yet there is no hard evidence that they extend the lives of healthy humans. The author notes that the human body is not a linear system; an intervention that is metabolically beneficial might, for example, impair adaptation to resistance training.
This problem is exacerbated by digitalization in Poland. Rapid access to data via IKP (Internet Patient Account) and e-prescriptions creates an illusion of agency. Patients receive raw test results but lack professional interpretation. This leads to an increase in private spending on diagnostics that are often unnecessary or misinterpreted without clinical supervision.
Summary
In a world where old age is no longer viewed as fate, but as a project for optimization, we risk turning biology into the ultimate determinant of class status. The author reminds us that health is primarily the capacity for adaptation, not perfect compliance with an algorithm.
We must ask ourselves: are we building a system that truly empowers the patient, or one in which the human being becomes merely a sum of monitored parameters managed by those who can afford it?
Frequently Asked Questions
How do geroscience and the longevity movement differ from traditional preventive medicine?
Traditional preventive medicine focuses on the early detection of diseases or counteracting specific infections and pathologies. Geroscience and the longevity movement shift intervention to a stage where disease is not yet present, focusing on modifying the biological mechanisms of the aging process itself to improve healthspan—the number of years lived in good health.
How does geroscience differ from traditional geriatrics, and what are the consequences of shifting from public prevention to personalized biohacking?
Geroscience differs from classical geriatrics in that instead of treating the effects of multimorbidity in elderly people, it aims to delay its onset by targeting common biological mechanisms of aging. The transition from public prevention to personalized biohacking represents a shift in objective from maximizing the health of the entire population within a limited budget to the private maximization of an individual's healthy lifespan.
Why do promising research results on anti-aging drugs in animals not automatically translate into extended life for healthy humans?
Animal results do not automatically translate to humans due to the evidence gap between biological activity and actual clinical effect. The organism is not a linear system, and theoretical mechanisms may not yield the desired result because processes that accelerate aging in one context may be essential for the proper functioning of the organism in another.
Why might the use of substances considered anti-aging (e.g., metformin) fail to produce the expected effects in healthy individuals?
The effect of metformin depends on the body's baseline metabolic state, and in healthy individuals, this intervention may be neutral or detrimental. For example, this drug may interfere with biological adaptation to resistance training, weakening muscle mass growth.
Why are popular longevity supplements often sold as effective despite a lack of hard evidence regarding the extension of human life?
These supplements are sold as effective through marketing that equates a substance's involvement in biological pathways or the improvement of biomarkers with an actual increase in lifespan. This exploits the so-called innovation paradox, where novel technologies enjoy greater prestige than proven prevention methods, despite being associated with greater scientific uncertainty.
What are the risks associated with shifting medicine toward early prevention and the optimization of aging?
The main risk is the danger of applying interventions to healthy individuals, where a low baseline risk increases the significance of adverse effects. Furthermore, aging may become a 'project,' leading to individuals being held responsible for their rate of aging and deepening social inequalities in access to healthy years of life.
Is modern longevity medicine merely a luxury project for the wealthy, or a real opportunity to improve population health?
Modern longevity medicine can become a real opportunity to improve population health if luxury innovations are transformed into accessible interventions. An example is geroscience, which aims to find cheap and safe methods to delay the onset of multiple age-related diseases simultaneously.
How does the digitalization of healthcare in Poland affect the relationship between the patient and access to professional diagnosis?
Digitalization provides patients with instantaneous access to medical data; however, this is not accompanied by equally fast access to its professional interpretation. A temporal asymmetry arises, where the ease of obtaining information on a smartphone clashes with staffing shortages and queues for specialists, which may encourage patients to finalize diagnoses on their own.
Will the introduction of central e-registration and the digitalization of the health system in Poland realistically shorten doctor queues?
Central e-registration can improve the allocation of shortages and facilitate access to information about available appointments, but it will not automatically increase the supply of services. Digitalization solves the coordination problem, but it does not replace missing medical staff nor increase the production capacity of the healthcare system.
Why does mere access to the internet and the Patient's Online Account (IKP) not guarantee equal access to healthcare?
Access to infrastructure alone is not synonymous with the digital, health, and interpretative competencies necessary to effectively utilize the system. Equal access is also limited by differences in economic, cultural, and social capital, which affect a patient's ability to navigate medical procedures efficiently and understand data correctly.
How does the digitalization of healthcare in Poland affect the patient-system relationship, and why does it lead to an increase in private spending on diagnostics?
Digitalization increases auditability symmetry, allowing patients to monitor their relationship with the system. However, the discrepancy between modern access to information (front office) and limited medical resources (back office) creates an expectation of immediacy. This leads to an increase in private spending on diagnostics, as patients buy time and a faster resolution of uncertainty to avoid long queues in the public system.
How do companies promote medical products in Poland, despite legal bans on advertising prescription drugs?
Companies build awareness of the problem by focusing on education about symptoms and diagnostics of specific diseases instead of advertising specific medications. By creating socially recognizable categories of suffering, they shape demand at the level of the health problem, which leads recipients toward medical services and final products.
Why does simply providing patients with their test results in digital form not guarantee equal access to health?
The mere provision of data masks the inequality in the ability to use it, because data equality is not knowledge equality. People with lower competencies are left only with raw results, while those with high cultural capital can independently acquire the necessary context and interpretation.
Does the digitalization of healthcare and access to data in the IKP (Internet Patient Account) actually facilitate treatment, or does it merely shift the responsibility for coordinating care onto the patient?
Digitalization and the IKP facilitate access to data, but they may lead to the outsourcing of care coordination to the patient, who becomes the primary carrier of information between specialists. Data infrastructure does not guarantee the integration of clinical reasoning, meaning that patients often have to manage fragmented decisions and results themselves.
What real threats and changes in the role of the patient does the digitalization of healthcare in Poland bring?
Digitalization carries the risk of deepening inequalities between patients with different levels of digital and cultural capital, as well as the threat of replacing medical care with algorithmic monitoring. It shifts the patient's role toward someone more organizationally proactive; however, it requires maintaining a balance between access to data and the right to professional medical interpretation.
